Ariana's explainable AI applied to mechanistic modelling of radiation-induced oxidative stress, bridging pre-clinical evidence to clinical outcomes. Ariana Pharma® and USIL Therapeutics, a Luxembourg-based biopharmaceutical company developing innovative cytoprotective therapies, today announced a collaboration to develop a mechanistic AI model supporting the clinical evaluation of UT-241 in acute radiation syndrome (ARS). The collaboration addresses a critical unmet medical n

Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer. The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise - transforming small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based, while leveraging Thomas's broad commercial expertise. The output is transparent and explainable, giving research tea

New Real-World Evidence study, "eXp AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk - A UK Biobank Case Study," published in The Pharmacogenomics Journal Ariana Pharmaceuticals is proud to announce the publication of a new Real-World Evidence study in The Pharmacogenomics Journal. This research showcases how Ariana's explainable AI (eXp AI) and proprietary KEM® platform can identify genomic biomarkers associated with mortality risk in toxic liver disease, us